Last reviewed 05/2018
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study was a double-blind randomised placebo controlled study of the effect of pravastatin in patients with a history of myocardial infarction or unstable angina who had a broad range of cholesterol levels.
Patients randomised to pravastatin showed a 20-30% relative risk reduction for a range of cardiovascular including:
- overall mortality
- myocardial infarction
This study suggests that any patient with a previous diagnosis of unstable angina or myocardial infarction should receive a statin.
For every 1000 patients treated for 6.1 years the following end-points were avoided:
- 30 deaths
- 28 non-fatal myocardial infarctions
- 9 non-fatal strokes
- 23 coronary bypass operations
- 20 coronary angioplasties
- 82 hospital admissions for unstable angina
- (1) LIPID study group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339, 1349-57